The future of endocannabinoid-oriented clinical research after CB 1 antagonists

Psychopharmacology

Volumn 205, Issue 1, 2009, Pages 171-174

  Le Foll, Bernard ^a   Gorelick, David A ^b   Goldberg, Steven R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction; CB1 receptor antagonist; Drug dependence; Obesity; Pharmacotherapy; Rimonabant; Safety

Indexed keywords

ALCOHOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABIS; ENDOCANNABINOID; FATTY ACID AMIDASE; NICOTINE; OPIATE; PSYCHOSTIMULANT AGENT; RIMONABANT; TARANABANT;

ADDICTION; ANXIETY; ARTHRITIS; CANNABIS ADDICTION; CLINICAL RESEARCH; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DRUG DEPENDENCE; DRUG INDICATION; DRUG INDUSTRY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; EUROPE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; LIVER DISEASE; METABOLIC SYNDROME X; NONHUMAN; NOTE; OBESITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SMOKING CESSATION; SPONTANEOUS ABORTION; SUICIDAL BEHAVIOR; TOBACCO DEPENDENCE; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; ENDOCANNABINOIDS; HUMANS; OBESITY; RECEPTOR, CANNABINOID, CB1;

EID: 67649418026     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1506-7     Document Type: Note

References (43)

1. S Batkai P Pacher Z Jarai JA Wagner G Kunos 2004 Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors Am J Physiol Heart Circ Physiol 287 H595 H600
2. M Beltramo N Stella A Calignano SY Lin A Makriyannis D Piomelli 1997 Functional role of high-affinity anandamide transport, as revealed by selective inhibition Science 277 1094 1097 (Pubitemid 27371630)
3. Cahill K, Ussher M (2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev Issue 4. Art. No.: CD005353. doi: 10.1002/14651858.CD005353.pub3
4. R Christensen PK Kristensen EM Bartels H Bliddal A Astrup 2007 Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 1706 1713 (Pubitemid 350100788)
5. JP Despres A Golay L Sjostrom 2005 Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 353 2121 2134 (Pubitemid 41653104)
6. JP Despres R Ross G Boka N Almeras I Lemieux 2008 Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat. The ADAGIO-Lipids Trial Arterioscler Thromb Vasc Biol 29 416
7. TJ De Vries AN Schoffelmeer 2005 Cannabinoid CB1 receptors control conditioned drug seeking Trends Pharmacol Sci 26 420 426 (Pubitemid 41039218)
8. KM Flegal BI Graubard DF Williamson MH Gail 2005 Excess deaths associated with underweight, overweight, and obesity JAMA 293 1861 1867 (Pubitemid 40548182)
9. Food and Drug Administration Endocrinologic and Metabolic Advisory (June 13, 2007) Briefing information, NDA 21-888 ZIMULTI (rimonabant)-Sanofi Aventis. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder. pdf (accessed March 13, 2008)
10. G Gobbi FR Bambico R Mangieri M Bortolato P Campolongo M Solinas T Cassano MG Morgese G Debonnel A Duranti A Tontini G Tarzia M Mor V Trezza SR Goldberg V Cuomo D Piomelli 2005 Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc Natl Acad Sci U S A 102 18620 18625 (Pubitemid 43011275)
11. OM Habayeb AH Taylor M Finney MD Evans JC Konje 2008 Plasma anandamide concentration and pregnancy outcome in women with threatened miscarriage JAMA 299 1135 1136
12. C Hampp AG Hartzema TL Kauf 2008 Cost-utility analysis of rimonabant in the treatment of obesity Value Health 11 389 399 (Pubitemid 351712976)
13. P Hossain B Kawar M El Nahas 2007 Obesity and diabetes in the developing world-a growing challenge N Engl J Med 356 213 215 (Pubitemid 46143224)
14. MA Huestis SJ Boyd SJ Heishman KL Preston D Bonnet G Le Fur DA Gorelick 2007 Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users Psychopharmacology (Berl) 194 505 515 (Pubitemid 47492992)
15. AA Izzo M Camilleri 2008 Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects Gut 57 1140 1155
16. D Jones 2008 End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7 961 962
17. Z Justinova P Munzar LV Panlilio S Yasar GH Redhi G Tanda SR Goldberg 2008 Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant Neuropsychopharmacology 33 2870 2877
18. S Kathuria S Gaetani D Fegley F Valino A Duranti A Tontini M Mor G Tarzia G La Rana A Calignano A Giustino M Tattoli M Palmery V Cuomo D Piomelli 2003 Modulation of anxiety through blockade of anandamide hydrolysis Nat Med 9 76 81 (Pubitemid 36098263)
19. B Le Foll TP George 2007 Treatment of tobacco dependence: integrating recent progress into practice CMAJ 177 1373 1380 (Pubitemid 350207193)
20. 1 receptor antagonists as promising new medications for drug dependence J Pharmacol Exp Ther 312 875 883 (Pubitemid 40293744)
21. B Le Foll B Forget HJ Aubin SR Goldberg 2008 Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies Addict Biol 13 239 252 (Pubitemid 351692986)
22. Merck (2008) Merck discontinues development of investigational medicine taranabant for obesity. http://www.merck.com/newsroom/press-releases/research- and-development/2008-1002.html
23. SE Nissen SJ Nicholls K Wolski J Rodes-Cabau CP Cannon JE Deanfield JP Despres JJ Kastelein SR Steinhubl S Kapadia M Yasin W Ruzyllo C Gaudin B Job B Hu DL Bhatt AM Lincoff EM Tuzcu 2008 Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial JAMA 299 1547 1560
24. CL Ogden MD Carroll LR Curtin MA McDowell CJ Tabak KM Flegal 2006 Prevalence of overweight and obesity in the United States, 1999-2004 JAMA 295 1549 1555
25. P Pacher S Batkai G Kunos 2006 The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol Rev 58 389 462 (Pubitemid 44394908)
26. FJ Pavon A Serrano V Perez-Valero N Jagerovic L Hernandez-Folgado FJ Bermudez-Silva M Macias P Goya FR de Fonseca 2008 Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats J Neuroendocrinol 20 Suppl 1 116 123 (Pubitemid 351552685)
27. P Reuter H Pollack 2006 How much can treatment reduce national drug problems? Addiction 101 341 347 (Pubitemid 43344817)
28. D Richardson RG Pearson N Kurian ML Latif MJ Garle DA Barrett DA Kendall BE Scammell AJ Reeve V Chapman 2008 Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis Arthritis Res Ther 10 R43
29. NA Rigotti D Gonzales LC Dale D Lawrence Y Chang 2009 A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain Addiction 104 266 276
30. J Rosenstock P Hollander S Chevalier A Iranmanesh 2008 SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes Diabetes Care 31 2169 2176
31. D Rucker R Padwal SK Li C Curioni DC Lau 2007 Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 335 1194 1199 (Pubitemid 350273303)
32. JD Salamone PJ McLaughlin K Sink A Makriyannis LA Parker 2007 Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions Physiol Behav 91 383 388 (Pubitemid 47016540)
33. Sanofi Aventis (2008) Sanofi-Aventis to discontinue all clinical trials with Rimonabant, Paris
34. AJ Scheen 2008 CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant J Neuroendocrinol 20 Suppl 1 139 146 (Pubitemid 351559287)
35. M Scherma P Fadda B Le Foll B Forget W Fratta SR Goldberg G Tanda 2008 The endocannabinoid system: a new molecular target for the treatment of tobacco addiction CNS Neurol Disord Drug Targets 7 468 481
36. M Scherma LV Panlilio P Fadda L Fattore I Gamaleddin B Le Foll Z Justinova E Mikics J Haller J Medalie J Stroik C Barnes S Yasar G Tanda D Piomelli W Fratta SR Goldberg 2008 Inhibition of anandamide hydrolysis by URB597 reverses abuse-related behavioral and neurochemical effects of nicotine in rats J Pharmacol Exp Ther 327 482 490
37. M Soyka G Koller P Schmidt OM Lesch M Leweke C Fehr H Gann KF Mann 2008 Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial J Clin Psychopharmacol 28 317 324
38. K Sugamura S Sugiyama T Nozaki Y Matsuzawa Y Izumiya K Miyata M Nakayama K Kaikita T Obata M Takeya H Ogawa 2009 Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages Circulation 119 28 36
39. G Tanda P Munzar SR Goldberg 2000 Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys Nat Neurosci 3 1073 1074 (Pubitemid 30828175)
40. U.S. Department of Health and Human Services (2004) The health consequences of smoking: a report of the surgeon general. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA
41. LF Van Gaal AM Rissanen AJ Scheen O Ziegler S Rossner 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 1389 1397 (Pubitemid 40523733)
42. LF Van Gaal AJ Scheen AM Rissanen S Rossner C Hanotin O Ziegler 2008 Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study Eur Heart J 29 1761 1771 (Pubitemid 352019811)
43. J Wiskerke T Pattij AN Schoffelmeer TJ De Vries 2008 The role of CB1 receptors in psychostimulant addiction Addict Biol 13 225 238 (Pubitemid 351692984)